Pharmacotherapy of smoking cessation

Indian Journal of Psychiatry

Volumn 56, Issue 1, 2014, Pages 87-95

  Jiloha, R C ^a  

^a G B PANT HOSPITAL   (India)

Author keywords

Nicotine replacement therapy; smoking cessation; varenicline

Indexed keywords

AMFEBUTAMONE; ANXIOLYTIC AGENT; CLONIDINE; MECAMYLAMINE; NALTREXONE; NICOTINE; NICOTINE GUM; NICOTINE LOZENGE; NICOTINE PATCH; NICOTINE VACCINE; NORTRIPTYLINE; VARENICLINE;

ARTICLE; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; MONOTHERAPY; NEUROBIOLOGY; NICOTINE REPLACEMENT THERAPY; SMOKING CESSATION; TOBACCO DEPENDENCE; WEIGHT GAIN; WITHDRAWAL SYNDROME;

EID: 84892698831     PISSN: 00195545     EISSN: 19983794     Source Type: Journal    
DOI: 10.4103/0019-5545.124726     Document Type: Article

References (77)

1. Ashton H, Stepney R. Smoking: Psychological and Pharmacology. London: Tavistock Publications; 1982.
2. Jiloha RC. Tobacco Use: Health and Behaviour. Delhi: New Age International; 2008.
3. Jiloha RC. Biological basis of tobacco addiction: Implications for smoking-cessation treatment. Indian J Psychiatry 2010; 52: 301-7.
4. Balfour DJ, Wright AE, Benwell ME, Birrell CE. The putative role of extra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependence. Behav Brain Res 2000; 113: 73-83.
5. Stauffer HP, Riedwyl H. Interaction and pH dependence of effects of nicotine and carbon monoxide in cigarette smoke inhalation experiments with rats. Agents Actions 1977; 7: 579-88.
6. Zhou FM, Liang Y, Dani JA. Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat Neurosci 2001; 4: 1224-9.
7. Tomkins DM, Sellers EM. Addiction and the brain: The role of neurotransmitters in the cause and treatment of drug dependence. CMAJ 2001; 164: 817-21.
8. Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996; 382: 255-7.
9. West R, Hajek P, Foulds J, Nilsson F, May S, Meadows A. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (Berl) 2000; 149: 198-202.
10. Pomerleau O, Adkins D, Pertschuk M. Predictors of outcome and recidivism in smoking cessation treatment. Addict Behav 1978; 3: 65-70.
11. Ikard FF, Tomkins S. The experience of affect as a determinant of smoking behavior: A series of validity studies. J Abnorm Psychol 1973; 81: 172-81.
12. Hughes JR, Goldstein MG, Hurt RD, Shiffman S. Recent advances in the pharmacotherapy of smoking. JAMA 1999; 281: 72-6.
13. Kenkel D, Chen L. Consumer information and tobacco use. In: Jha P, Chaloupka FJ, editors. Tobacco Control in Developing Countries. Oxford: Oxford University Press; 2000. p. 77-214.
14. Russell MA. The nicotine addiction trap: A 40-year sentence for four cigarettes. Br J Addict 1990; 85: 293-300.
15. DiFranza JR, Rigotti NA, McNeill AD, Ockene JK, Savageau JA, St Cyr D, et al. Initial symptoms of nicotine dependence in adolescents. Tob Control 2000; 9: 313-9.
16. Mansvelder HD, McGehee DS. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron 2000; 27: 349-57.
17. Brownell KD. Dieting and the search for the perfect body: Where physiology and culture collide. Behav Ther 1991; 22: 1-12.
18. Hajek P, Jackson P, Belcher M. Long-term use of nicotine chewing gum. Occurrence, determinants and effect on weight gain. JAMA 1988; 260: 1593-6.
19. Moffatt RJ, Owens SG. Cessation from cigarette smoking: Changes in body weight, body composition, resting metabolism and energy consumption. Metabolism 1991; 40: 465-70.
20. Perkins KA, Epstein LH, Marks BL, Stiller RL, Jacob RG. The effect of nicotine on energy expenditure during light physical activity. N Engl J Med 1989; 320: 898-903.
21. Williams M, Sullivan JP, Arneric SP. Neuronal nicotine acetylcholine receptors. Drug News Perspect 1994; 7: 205-23.
22. Pirie PL, McBride CM, Hellerstedt W, Jeffery RW, Hatsukami D, Allen S, et al. Smoking cessation in women concerned about weight. Am J Public Health 1992; 82: 1238-43.
23. Crisp AH. Regulation of the self in adolescence with particular reference to anorexia nervosa. Trans Med Soc Lond 1982; 99-100: 67-74.
24. Williamson DF, Madans J, Anda RF, Kleinman JC, Giovino GA, Byers T. Smoking cessation and severity of weight gain in a national cohort. N Engl J Med 1991; 324: 739-45.
25. Killen JD, Fortmann SP, Newman B. Weight change among participants in a large sample minimal contact smoking relapse prevention trial. Addict Behav 1990; 15: 323-32.
26. Perkins KA, Levine MD, Marcus MD, Shiffman S. Addressing women's concerns about weight gain due to smoking cessation. J Subst Abuse Treat 1997; 14: 173-82.
27. Gilbert RM, Pope MA. Early effects of quitting smoking. Psychopharmacology (Berl) 1982; 78: 121-7.
28. Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: The National Comorbidity Survey. Am J Psychiatry 1994; 151: 979-86.
29. Craig D, Parrott A, Coomber JA. Smoking cessation in women: Effects of the menstrual cycle. Int J Addict 1992; 27: 697-706.
30. Borrelli B, Bock B, King T, Pinto B, Marcus BH. The impact of depression on smoking cessation in women. Am J Prev Med 1996; 12: 378-87.
31. Glassman AH. Cigarette smoking: Implications for psychiatric illness. Am J Psychiatry 1993; 150: 546-53.
32. Ward KD, Klesges RC, Zbikowski SM, Bliss RE, Garvey AJ. Gender differences in the outcome of an unaided smoking cessation attempt. Addict Behav 1997; 22: 521-33.
33. Campbell IA, Lyons E, Prescott RJ. Stopping smoking. Do nicotine chewing-gum and postal encouragement add to doctors' advice. Practitioner 1987; 231: 114-7.
34. Gamberino WC, Gold MS. Neurobiology of tobacco smoking and other addictive disorders. Psychiatr Clin North Am 1999; 22: 301-12.
35. Fiore MC, Bailey WC, Cohen SJ. Treating Tobacco Use and Dependence. A Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services; 2000.
36. Crowe RR, Kramer JR, Hesselbrock V, Manos G, Bucholz KK. The utility of the Brief MAST' and the CAGE' in identifying alcohol problems: Results from national high-risk and community samples. Arch Fam Med 1997; 6: 477-83.
37. Morton JL, Jones TV, Manganaro MA. Performance of alcoholism screening questionnaires in elderly veterans. Am J Med 1996; 101: 153-9.
38. Lairson DR, Harrist R, Martin DW, Ramby R, Rustin TA, Swint JM, et al. Screening for patients with alcohol problems: Severity of patients identified by the CAGE. J Drug Educ 1992; 22: 337-52.
39. Fiore MC, Jaen CR, Baker TB. Treating tobacco use and dependence: 2008 update. US Department of Health and Human Services; 2008. Available from: http: //www. surgeongeneral. gov/tobacco/treating-tobacco-use08. pdf. [Last accessed on 2011 Oct 17].
40. US Department of Health and Human Services. Quick Reference Guide for Clinicians: Treating Tobacco Use and Dependence. Washington (DC): The Department; 2000. Available from: http: //www. ahrq. gov/clinic/tobacco/ tobaqrg. pdf. [Last accessed on 2008 May 12].
41. Tønnesen P, Tonstad S, Hjalmarson A, Lebargy F, Van Spiegel PI, Hider A, et al. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J Intern Med 2003; 254: 184-92.
42. Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS. Sustained-release bupropion for smoking cessation in African Americans: A randomized controlled trial. JAMA 2002; 288: 468-74.
43. Henningfield JE, Jasinki DR. Pharmacological basis for nicotine replacement. In: Pomerleau OF, Pomerleau CS, Fagerstrom KO, Henningfield JE, Hughjes JR, editors. Nicotine Replacement: A Critical Evaluation. New York: Alan R Liss; 1988.
44. Leventhal H, Cleary PD. The smoking problem: A review of the research and theory in behavioral risk modification. Psychol Bull 1980; 88: 370-405.
45. Ferno O, Lichtneckert S, Lundgreen CA. A substitute for tobacco smoking. Psychopharmacologia 1973; 31: 301-4.
46. Malcolm R, Currey HS, Mitchell MA, Keil JE. Silver acetate gum as a deterrent to smoking. Chest 1986; 90: 107-11.
47. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 1986; 43: 289-94.
48. Henningfield JE, Sampson A, Nemeth-Coslett R. Effect of nicotine replacement in tobacco withdrawal. Presented at the American Psychological Convention, Washington DC; 1986.
49. West R, Schneider N. Craving for cigarettes. Br J Addict 1987; 82: 407-15.
50. Fagerstrom KO. Reducing the weight gain after stopping smoking. Addict Behav 1987; 12: 91-3.
51. Stitzer ML, Gross J. Smoking relapses: The role of pharmacological and behavioural factors. In: Pomerleau OF, Pomerleau CS, Fagerstrom KO, Henningfield JE, Hughes JR, editors. Nicotine Replacement: A Critical Evaluation. New York: Alan R Liss Inc. ; 1988.
52. Hjalmarson AI. Effect of nicotine chewing gum in smoking cessation. A randomized, double blind placebo-controlled study studies. J Am Med Assoc 1984; 252: 2835-8.
53. Benowitz NL. Pharmacology of nicotine: Addiction and therapeutics. Annu Rev Pharmacol Toxicol 1996; 36: 597-613.
54. Shiffman S, Dresler CM, Hajek P, Gilburt SJ, Targett DA, Strahs KR. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 2002; 162: 1267-76.
55. Choi JH, Dresler CM, Norton MR, Strahs KR. Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res 2003; 5: 635-44.
56. Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA 1994; 271: 1940-7.
57. Hurt RD, Offord KP, Croghan IT, Croghan GA, Gomez-Dahl LC, Wolter TD, et al. Temporal effects of nicotine nasal spray and gum on nicotine withdrawal symptoms. Psychopharmacology (Berl) 1998; 140: 98-104.
58. Sweeney CT, Fant RV, Fagerstrom KO, McGovern JF, Henningfield JE. Combination nicotine replacement therapy for smoking cessation: Rationale, efficacy and tolerability. CNS Drugs 2001; 15: 453-67.
59. Schneider NG, Olmstead RE, Franzon MA, Lunell E. The nicotine inhaler: Clinical pharmacokinetics and comparison with other nicotine treatments. Clin Pharmacokinet 2001; 40: 661-84.
60. Schuh KJ, Schuh LM, Henningfield JE, Stitzer ML. Nicotine nasal spray and vapor inhaler: Abuse liability assessment. Psychopharmacology (Berl) 1997; 130: 352-61.
61. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337: 1195-202.
62. Miller NS, Brady KT. Addictive disorders. Psychiatr Clin North Am 2004; 27: xi-xviii.
63. Johnston JA, Hughes AR, Ascher JA. Evaluation of safety and tolerability of bupropion SR as an ad to smoking cessation. Poster presentation at the 5th Annual Meeting of The Society for Research on Nicotine and Tobacco. San Diego CA. 1999.
64. Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D. A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 1998; 158: 2035-9.
65. Hall SM, Humfleet GL, Reus VI, Muñoz RF, Hartz DT, Maude-Griffin R. Psychological intervention and antidepressant treatment in smoking cessation. Arch Gen Psychiatry 2002; 59: 930-6.
66. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA 2006; 296: 56-63.
67. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, et al. Varenicline: An alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005; 48: 3474-7.
68. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 2006; 296: 47-55.
69. Rao J, Shankar PK. Varenicline: For smoking cessation. Kathmandu Univ Med J (KUMJ) 2009; 7: 162-4.
70. Kaur K, Kaushal S, Chopra SC. Varenicline for smoking cessation: A review of the literature. Curr Ther Res 2009; 70: 35-54.
71. Jain R, Jhanjee S, Veena J, Gupta T. Nicotine and tobacco research. Oxford J 2013.
72. Stolerman IP. Discriminative stimulus properties in nicotine: Correlations with nicotine binding. Proceedings of the International Symposium on Tobacco Smoking and Health: A Neuro-biologic Approach. 1986.
73. Goldberg SR, Spealman RD, Risner ME, Henningfield JE. Control of behavior by intravenous nicotine injections in laboratory animals. Pharmacol Biochem Behav 1983; 19: 1011-20.
74. Henningfield JE, Goldberg SR. Control of behavior by intravenous nicotine injections in human subjects. Pharmacol Biochem Behav 1983; 19: 1021-6.
75. Tennant FS, Traver AL, Rawson RA. Clinical evaluation of mecamylamine for withdrawal from nicotine dependence. In: Harrison LS, editor. Problems of Drug-Dependence 1983 NIDA. Research Monograph UD Department of Health and Human Services; 1984.
76. Kumar R, Vijayan VK. Smoking cessation programs and other preventive strategies for chronic obstructive pulmonary disease. J Assoc Physicians India 2012; 60 Suppl: 53-6.
77. Paddock C. Vaccine to treat nicotine addiction steps closer to market as companies agree option deal. Medical News Today. [2009 Nov 18].